| __timestamp | Exelixis, Inc. | Geron Corporation |
|---|---|---|
| Wednesday, January 1, 2014 | 189101000 | 20707000 |
| Thursday, January 1, 2015 | 96351000 | 17831000 |
| Friday, January 1, 2016 | 95967000 | 18047000 |
| Sunday, January 1, 2017 | 112171000 | 11033000 |
| Monday, January 1, 2018 | 182257000 | 13432000 |
| Tuesday, January 1, 2019 | 336964000 | 52072000 |
| Wednesday, January 1, 2020 | 547851000 | 51488000 |
| Friday, January 1, 2021 | 693716000 | 85727000 |
| Saturday, January 1, 2022 | 891813000 | 95518000 |
| Sunday, January 1, 2023 | 1044071000 | 125046000 |
| Monday, January 1, 2024 | 910408000 |
Igniting the spark of knowledge
In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Exelixis, Inc. and Geron Corporation have demonstrated contrasting approaches to R&D investment. From 2014 to 2023, Exelixis increased its R&D spending by over 450%, reaching a peak in 2023. This surge underscores Exelixis's aggressive pursuit of new therapies and treatments. In contrast, Geron Corporation's R&D expenses grew by approximately 500% during the same period, albeit from a smaller base, reflecting a more measured but steady commitment to innovation. The data reveals that while both companies prioritize R&D, Exelixis's larger financial commitment suggests a more robust pipeline of potential breakthroughs. As the biotech landscape evolves, these investments could shape the future of medical advancements.
Research and Development Expenses Breakdown: Novo Nordisk A/S vs Exelixis, Inc.
Who Prioritizes Innovation? R&D Spending Compared for GSK plc and Exelixis, Inc.
Research and Development Investment: Insmed Incorporated vs Exelixis, Inc.
R&D Insights: How Sarepta Therapeutics, Inc. and Exelixis, Inc. Allocate Funds
Exelixis, Inc. vs Protagonist Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Exelixis, Inc. and Arrowhead Pharmaceuticals, Inc.
R&D Spending Showdown: Exelixis, Inc. vs Wave Life Sciences Ltd.
R&D Insights: How Exelixis, Inc. and Celldex Therapeutics, Inc. Allocate Funds
R&D Spending Showdown: Exelixis, Inc. vs Taro Pharmaceutical Industries Ltd.
Research and Development Expenses Breakdown: Amneal Pharmaceuticals, Inc. vs Geron Corporation
Research and Development Investment: Soleno Therapeutics, Inc. vs Geron Corporation
Comparing Innovation Spending: Geron Corporation and Viridian Therapeutics, Inc.